跳到正文
原文
Nature 健康护理主题·· 29 天前AI 评分18

Münzel等回复关于尼古丁替代疗法(NRT)与尼古丁消费品的区分

Reply to ‘Distinguishing between nicotine replacement therapies and nicotine-containing consumer products’

AI 导读

Münzel等回复Berlin和Thomas的来信,确认尼古丁替代疗法(NRT)是独立于其他尼古丁消费品的严评药品,但认为短期临床试验证据未解决NRT心血管安全性问题。作者强调尼古丁包括NRT在内的对心血管的影响并非生物学惰性,并欢迎澄清立场。

正文
  • Correspondence
  • Published: 22 October 2026

Nature Reviews Cardiology (2026) Cite this article

We thank Berlin and Thomas for their Correspondence on our Review (Münzel, T. et al. Nicotine-containing products and the cardiovascular system: mechanisms and global health implications. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01331-6; 2026)1 and for the issues raised (Berlin, I. & Thomas, D. Distinguishing between nicotine replacement therapies and nicotine-containing consumer products. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01362-z; 2026)2; we welcome the opportunity to clarify our position on nicotine replacement therapy (NRT). We agree that NRT occupies a distinct regulatory and clinical category from that of other nicotine-containing consumer products: NRT is a rigorously evaluated, quality-controlled medication with a well-established net benefit for smoking cessation, and nothing in our Review was intended to discourage its prescription.

However, we do not agree that the evidence from short-term clinical trials cited by Berlin and Thomas settles the question of the cardiovascular safety of NRT, and we think that their Correspondence illustrates precisely the point that we raised in our Review — that the cardiovascular effects of nicotine, including from NRT, should not be regarded as biologically inert.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

27.99 € / 30 days cancel any time

Learn more

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Münzel, T. et al. Nicotine-containing products and the cardiovascular system: mechanisms and global health implications. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01331-6 (2026).

    Article  PubMed  Google Scholar 

  2. Berlin, I. & Thomas, D. Distinguishing between nicotine replacement therapies and nicotine-containing consumer products. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01362-z (2026).

    Article  Google Scholar 

  3. Mills, E. J., Thorlund, K., Eapen, S., Wu, P. & Prochaska, J. J. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 129, 28–41 (2014).

    Article  CAS  PubMed  Google Scholar 

  4. Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C. & Lancaster, T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst. Rev. 5, CD000146 (2018).

    PubMed  PubMed Central  Google Scholar 

  5. Dollerup, J. et al. Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. Clin. Epidemiol. 9, 231–243 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mills, E. J., Wu, P., Lockhart, I., Wilson, K. & Ebbert, J. O. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob. Induc. Dis. 8, 8 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Münzel, T., Crea, F., Rajagopalan, S. & Lüscher, T. F. Nicotine and the cardiovascular system: unmasking a global public health threat. Eur. Heart J. 47, 1764–1781 (2026).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany

    Thomas Münzel, Marin Kuntic, Julia Lurz & Andreas Daiber

  2. German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany

    Thomas Münzel, Marin Kuntic & Andreas Daiber

  3. Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, USA

    John F. Keaney

  4. Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina – Gemelli Isola, Rome, Italy

    Filippo Crea

  5. Heart Division, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

    Thomas F. Lüscher

  6. School of Cardiovascular and Metabolic Medicine and Sciences, King’s College London, London, UK

    Thomas F. Lüscher

  7. National Heart and Lung Institute, Imperial College, London, UK

    Thomas F. Lüscher

  8. Center for Molecular Cardiology, University of Zurich, Schlieren-Zurich, Switzerland

    Thomas F. Lüscher

  9. University Hospitals, Harrington Heart and Vascular Institute, Case Western Reserve School of Medicine, Cleveland, OH, USA

    Sanjay Rajagopalan

Authors

  1. Thomas Münzel
  2. Marin Kuntic
  3. John F. Keaney
  4. Julia Lurz
  5. Filippo Crea
  6. Thomas F. Lüscher
  7. Sanjay Rajagopalan
  8. Andreas Daiber

Corresponding author

Correspondence to Thomas Münzel.

Ethics declarations

Competing interests

The authors declare no competing interests.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Münzel, T., Kuntic, M., Keaney, J.F. et al. Reply to ‘Distinguishing between nicotine replacement therapies and nicotine-containing consumer products’. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01361-0

Download citation

  • Published: 22 October 2026

  • Version of record: 22 October 2026

  • DOI: https://doi.org/10.1038/s41569-026-01361-0

来源:Nature 健康护理主题 · nature.com